After an early focus on AstraZeneca and months of turmoil, the European Union is pivoting away from the company’s vaccine. It has reached agreement for a faster rollout of the Pfizer-BioNTech shot.

After an early focus on AstraZeneca and months of turmoil, the European Union is pivoting away from the company’s vaccine. It has reached agreement for a faster rollout of the Pfizer-BioNTech shot.